Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist
Journal Title: The AAPS Journal - Year 2010, Vol 12, Issue 4
Abstract
Taranabant is a cannabinoid-1 receptor inverse agonist developed for the treatment of obesity. A population model was constructed to facilitate the estimation of pharmacokinetic parameters and to identify the influence of selected covariates. Data from 12 phase 1 studies and one phase 2 study were pooled from subjects administered single and multiple oral doses of taranabant ranging from 0.5 to 8 mg. A total of 6,834 taranabant plasma concentrations from 187 healthy and 385 obese subjects were used to develop the population model in NONMEM. A standard covariate analysis using forward selection (α = 0.05) and backward elimination (α = 0.001) was conducted. A three-compartment model with first-order absorption and elimination adequately described plasma taranabant concentrations. The population mean estimates for apparent clearance and apparent steady-state volume of distribution were 25.4 L/h and 2,578 L, respectively. Statistically significant covariate effects were modest in magnitude and not considered clinically relevant (the effects of body mass index (BMI) and creatinine clearance (CrCL) on apparent clearance; BMI, age, CrCL, and gender on apparent volume of the peripheral compartment and age on apparent intercompartmental clearance). The pharmacokinetic profile of taranabant can adequately be described by a three-compartment model with first-order absorption and elimination. Clinical dose adjustment based on covariates effects is not warranted.
Authors and Affiliations
Xiujiang (Susie) Li, Jace Nielsen, Brenda Cirincione, Hankun Li, Carol Addy, John Wagner, Alan Hartford, Ngozi Erondu, Ira Gantz, Jerry Morgan, Julie Stone
Keywords
Related Articles
- EP ID EP681417
- DOI 10.1208/s12248-010-9212-2
- Views 74
- Downloads 0
Ligand Binding Assays in the 21st Century Laboratory: Platforms
A high level of precision is required to generate reproducible bioanalytical results for the measurement of drug, biomarker concentrations, and detection of immunogenic responses. Precision for LBAs analytical assays use...
Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease
Parkinson’s disease is an age-related degenerative disorder of the central nervous system that often impairs the sufferer’s motor skills and speech, as well as other functions. Symptoms can include tremor...
Critical Variables Associated with Nonbiodegradable Osmotically Controlled Implants
Osmotically controlled implants yield precise zero-order drug delivery kinetics and are utilized in a number of applications. The implants deliver drugs for extended periods (weeks to years) and exhibit good in vivo/in v...
Protein binding predictions in infants
Plasma binding protein levels are lower in the newborn than in the adult and gradually increase with age. At birth, human serum albumin (HSA) concentrations are close to adult levels (75%–80%), while alpha 1-acid...
Informatic Tools and Approaches in Postmarketing Pharmacovigilance Used by FDA
The safety profile of newly approved drugs and therapeutic biologics is less well developed by pre-marketing clinical testing than is the efficacy profile. The full safety profile of an approved product is established du...